Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

NEW EPISODE
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
NEW EPISODE
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits
MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
- Tiffany Traina, MD, FASCO
Key Differences in Pulmonary and Extrapulmonary NEC Management
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®
Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS; Lowell B. Anthony, MD, FACP
- Alexandria May, PharmD, BCPS
- Lowell B. Anthony, MD, FACP
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Project Oncology®
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP; Rohit Thummalapalli, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Rohit Thummalapalli, MD
Optimizing Treatment Intensity in Early-Stage TNBC
Optimizing Treatment Intensity in Early-Stage TNBC
Project Oncology®
Optimizing Treatment Intensity in Early-Stage TNBC
Roberto Leon-Ferre, MD
- Roberto Leon-Ferre, MD
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE Virtual Event
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
1.50 credits

Medical News

Medical News
First-Line Pemigatinib in Fgfr2-Rearranged Cholangiocarcinoma
06/12/2026
Read more
Medical News
Robot-Assisted Versus Conventional Minimally Invasive Oesophagectomy
06/12/2026
Read more
Medical News
Zanidatamab Regimens vs Trastuzumab in HER2 Positive GEA
06/11/2026
Read more
Medical News
Elinzanetant Eases Vasomotor Symptoms In Breast Cancer Trial
06/10/2026
Read more

CME/CE

Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
MinuteCE®
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
MinuteCE®
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits
MinuteCE®
Talking Through Treatment: Patient–Clinician Dialogue on Perioperative Immunotherapy in Locally Advanced HNSCC
Jennifer Johnson, MD, PhD; Adam J. Luginbuhl, MD
0.50 credits 5 episodes
- Jennifer Johnson, MD, PhD
- Adam J. Luginbuhl, MD
0.50 credits 5 episodes
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
MinuteCE®
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
Adam J. Luginbuhl, MD; Jennifer Johnson, MD, PhD
0.50 program credits
- Adam J. Luginbuhl, MD
- Jennifer Johnson, MD, PhD
0.50 program credits

Clinical Practice

6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Project Oncology®
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Steve Jackson, PharmD; Lyudmila A. Bazhenova, MD
- Steve Jackson, PharmD
- Lyudmila A. Bazhenova, MD
NEW EPISODE
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Project Oncology®
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP; Andrew E. Hendifar, MD
- Brian P. McDonough, MD, FAAFP
- Andrew E. Hendifar, MD
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Project Oncology®
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP; Rohit Thummalapalli, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Rohit Thummalapalli, MD

Programs

DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Project Oncology®
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Alexandria May, PharmD, BCPS; Chandrikha Chandrasekharan, MBBS
- Alexandria May, PharmD, BCPS
- Chandrikha Chandrasekharan, MBBS
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
MinuteCE®
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits